By Kim Han-joo
SEOUL, Nov. 26 (Yonhap) -- South Korean biopharmaceutical firm Celltrion Inc. said Tuesday that its drug Remsima SC for the treatment of autoimmune diseases has won sales approval in Europe.
On Monday (local time), the European Medicines Agency (EMA) gave the green light to Celltrion's application to sell the subcutaneous (SC) version of Remsima, a biosimilar copy of Janssen Biotech, Inc.'s Remicade, according to the company.
Remsima, administered through intravascular injections, is used in the treatment of a number of diseases, from rheumatoid arthritis to Crohn's disease, Celltrion said. The SC version allows patients to conveniently inject it by themselves, unlike the intravenous formulation that requires patients to visit hospitals.
The authorization comes nearly a year after Celltrion sent the application to the EMA.
Celltrion said it intends to improve its competitiveness in the European autoimmune disease therapeutic agent market with the existing Remsima and Remsima SC.
Celltrion said it plans to register patents for its autoimmune disease therapeutic antibody biosimilar in over 130 countries.
The company said Remsima SC will be under patent protection over the next 20 years, helping enhance Celltrion's competitiveness in the global autoimmune disease therapeutic agent market.
Subscription models, another way out for slump-hit retailers amid contactless trend
One month into eased social distancing, S. Korea wrestles with cluster infections, cases with unknown routes
Virus outbreak sheds light on overlooked side of highly touted 'fast' delivery services
Livestreaming platform, another alternative tool for retailers in 'non-contact' era
Debate brews over expansion of employment insurance amid coronavirus outbreak